Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2NET 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Small Cell Lung Carcinoma 10Sarcoma 8Breast Neoplasms 8Carcinoma, Hepatocellular 7Lung Neoplasms 6Stomach Neoplasms 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma 4Non-squamous Non-small Cell Lung Cancer 3NSCLC 3Glioma 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Thyroid Neoplasms 2Pheochromocytoma 2Paraganglioma 2Neoplasms 2Liver Neoplasms 2Gynecological Cancer 2Extensive Stage Small Cell Lung Cancer 2Esophageal Neoplasms 2Endometrial Neoplasms 2Digestive System Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Solid Tumor 2Squamous Non-small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Folfox protocol 3Drug Therapy 3Cisplatin 3apatinib 2anlotinib 2Paclitaxel 2Oxaliplatin 2Fluorouracil 2Capecitabine 2sintilimab 1pyrotinib 1pemigatinib 1huachansu 1donafenib 1Trastuzumab 1Sorafenib 1Radiotherapy 1Physical Conditioning, Human 1Microspheres 1Leucovorin 1Immune Checkpoint Inhibitors 1Docetaxel 1Chemoradiotherapy 1Bevacizumab 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Digestive System Neoplasms × anlotinib × Clear all
NCT05262335 2023-11-28

ALTER-G-001

Ruijin Hospital

Phase 2 Unknown
116 enrolled
Gastrointestinal

Digestive System Neoplasms

NCT04207463 2020-06-17

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
150 enrolled
EndocrineGastrointestinalNET

Digestive System Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡